english.prescrire.org > Spotlight > 100 most recent > Attenuated chikungunya vaccine (Ixchiq°)

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Attenuated chikungunya vaccine (Ixchiq°)

 Marketing Authorisations  The first chikungunya vaccine to have been authorised in the European Union is a live attenuated virus derived from a strain isolated on Reunion Island in 2006. Is this vaccine effective at preventing chikungunya infections and their complications? Does it slow transmission during an epidemic? Is it useful for travellers visiting an area where chikungunya is endemic? And what are its adverse effects?
Full article available for download by subscribers

 ©Prescrire 1 December 2025

Source: "Attenuated chikungunya vaccine (Ixchiq°)" Prescrire Int 2025; 34 (276): 285-288. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information